Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anlotinib + Bemotuzumab + Nab-paclitaxel in ICI-resistant advanced biliary tract cancer
ChiCTR2600129413Phase 4Not yet recruiting
- Sponsor
- Hunan Provincial People's Hospital
- Start
- Aug 2026
- Modality
- Small Molecules, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of anlotinib, bemotuzumab and nab-paclitaxel in gallbladder cancer, intrahepatic cholangiocarcinoma (ICC), cholangiocarcinoma (CCA) and 1 more, sponsored by Hunan Provincial People's Hospital. Primary endpoint: Objective Response Rate (ORR). Planned start Aug 2026; status: not yet recruiting.
02
Drugs
anlotinibbemotuzumabnab-paclitaxel
03
Conditions
gallbladder cancerintrahepatic cholangiocarcinoma (ICC)cholangiocarcinoma (CCA)biliary cancer
Beyond the preview
Go deeper on ChiCTR2600129413.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600129413.